에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

JP Morgan analyst Tami Zakaria maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Neutral and lowers the price target from $420 to $375.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Cummins, Lowers Price Target to $375

WIIM

MSTR

Strategy shares are trading lower after the company announced a public offering of 5 million Series A shares.

JP Morgan analyst Tami Zakaria maintains PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) with a Overweight and lowers the price target from $132 to $121.

PCAR

JP Morgan Maintains Overweight on PACCAR, Lowers Price Target to $121

Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.09) by 10.09 percent. This is a 24.05 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $3.554 million which missed the analyst consensus estimate of $3.601 million by 1.30 percent. This is a 40.79 percent decrease over sales of $6.002 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

COYA

Coya Therapeutics FY 2024 GAAP EPS $(0.98) Beats $(1.09) Estimate, Sales $3.554M Miss $3.601M Estimate

REE Automotive shares are trading lower after the company announced the pricing of a $27 million registered direct offering of 6,376,631 shares at $4.25 per share. The company entered into a non-binding MOU with a global technology company.

TSLA

Tesla shares are trading lower. The stock may be moving down after competitor XPeng reported Q4 financial results and announced over 91.5K EV deliveries. The company also stated it expects massive growth for Q1.

JP Morgan analyst Sebastiano Petti maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Overweight and raises the price target from $265 to $270.

TMUS

JP Morgan Maintains Overweight on T-Mobile US, Raises Price Target to $270

Wolfe Research suggested that&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has the potential to generate a staggering $30-40 billion in revenue from its business messaging services, a prospect currently undervalued by the market.
What Happened: Analysts at Wolfe Research anticipate a &#8220;modest near-term upside&#8221; that could positively influence Meta&#8217;s FY25/26 Other-FOA revenue predictions, according to <a href="https://au.investing.com/news/stock-market-news/metas-business-messaging-opportunity-stands-at-3040b-3734762">a</a> report by Investing.com.
At present, WhatsApp's business messaging contributes a mere $1.5 to $2 billion annually. However, Meta&#8217;s plan to integrate AI agents into small businesses for customer service could significantly increase this revenue.
Wolfe Research stated, &#8220;We&nbsp;think it offers Meta a&nbsp;$30 &#8211; $40B revenue TAM.&#8221; The firm also highlighted that Meta is uniquely positioned to tap into this market due to WhatsApp&#8217;s existing user base.
These&nbsp;estimates take into account automation adoption, the total addressable market for customer service, and the number of businesses already operating on WhatsApp. They forecast that as automation progresses to manage more complex inquiries, &#8220;business messaging could accelerate,&#8221; particularly in key markets such as India, Indonesia, and Brazil.
Wolfe Research also foresees a promising medium-term opportunity, projecting &#8220;a&nbsp;high-single-digit to low-double-digit billion-dollar incremental&nbsp;revenue opportunity&#8221; in the next few years. This expansion could strengthen Meta&#8217;s platform engagement, particularly among businesses that rely on WhatsApp for customer interactions.
SEE ALSO: <a href="https://www.benzinga.com/25/03/44373082/former-nasa-astronaut-predicts-mars-travel-still-15-years-away-not-5-years-as-elon-musk-alludes-to">Former NASA Astronaut Predicts Mars Travel Still 15 Years Away: &#8216;Not 5 Years As Elon Musk Alludes To&#8217;</a>
Why It Matters: This prediction comes at a time when <a href="https://www.benzinga.com/general/social-media/25/03/44363736/zuckerbergs-global-push-meta-faces-scrutiny-over-privacy-free-speech-regulatory-tactics">Meta&#8217;s global expansion efforts</a> are under intense scrutiny, following serious allegations from former executive Sarah Wynn-Williams.
In her memoir &#8220;Careless People&#8221; and a whistleblower complaint filed with the SEC, Wynn-Williams accused Meta and CEO Mark Zuckerberg of taking extreme steps to penetrate the Chinese market while simultaneously engaging in controversial lobbying tactics in India.
These concerns arise at a crucial moment as Meta revises its policies in response to shifting political dynamics, while Zuckerberg positions the company as a key force in American tech diplomacy. Last Week President Donald Trump also indicated that Meta Platforms <a href="https://www.benzinga.com/markets/25/03/44323127/trump-suggests-meta-may-invest-up-to-60-billion-in-the-us-by-the-end-of-2025">could invest </a>up to $ 60 billion into the U.S. by the end of 2025. 
The potential revenue from business messaging boost could be a game-changer for Meta, especially if it successfully navigates the regulatory challenges it currently faces.
Meta platform stock climbed 12.45% over the past six months.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/03/44321211/tesla-charging-stations-cut-from-rebate-program-by-canadian-province-most-people-would-support-their-removal-from-subsidy-list-says-minister">Tesla Charging Stations Cut From Rebate Program By Canadian Province: &#8216;Most People Would Support Their Removal&#8217; From Subsidy List, Says Minister</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

Meta Could Rake In $30-40 Billion In Revenue From WhatsApp Business Messaging, Predicts Analyst

Presearch, a decentralized meta-search engine, has advanced its Web3 transition by launching its PRE token in beta on Base, a layer 2 blockchain supported by Coinbase.
The company, which avoids tracking users or selling their data to advertisers, announced this development as part of its ongoing effort to create a fully decentralized search ecosystem, enhancing accessibility and efficiency for its users and advertisers while addressing long-standing challenges like high transaction fees.
The shift to Base Layer-2, designed to improve scalability and reduce costs for on-chain activities, enables Presearch to offer self-custodial staking mechanisms, allowing users to maintain full control over their assets while earning or staking PRE tokens for keyword ads.
This upgrade tackles issues such as low liquidity and expensive transactions that have previously hindered PRE's adoption. 
Presearch's decentralized node network, which processes search results through a global community, ensures transparency and reduces biases common in traditional search engines. 
The company reports over 150,000 active monthly users, 13 million monthly impressions, and more than 400,000 daily searches, reflecting its growing influence in bridging traditional internet users with the crypto space.
Also Read: <a href="https://www.benzinga.com/news/ipos/25/03/44367379/global-client-advisory-group-affiliate-files-for-175-million-ipo-targeting-crypto-digital-security-ventures">Global Client Advisory Group Affiliate Files For $175 Million IPO, Targeting Crypto, Digital Security Ventures</a>
"Base will expand our user base, increase liquidity, and boost community engagement, fueling further adoption and growth of the Presearch ecosystem," said Tim Enneking, CEO of Presearch. 
The platform's search-to-earn model rewards users with PRE tokens for each search, with additional earnings through its staking system—the more PRE staked, the higher the per-search reward. 
Presearch's PRE ButterFlyWheel mechanism integrates decentralized finance (DeFi) tools to enhance liquidity, token velocity, and search volume, creating a self-reinforcing cycle that supports its ecosystem. 
"Users deserve a fully decentralized search engine that completely respects their privacy and participation," Enneking added, highlighting the platform's aim to counter the echo chambers prevalent in conventional search engines.
Presearch's Web3 focus has also attracted advertisers seeking privacy-first platforms, with partners like eToro, Bitcoin.com, Ledger, and KuCoin joining its network. 
The company's infrastructure, powered by over 250 digital assets and a community-driven approach, offers a fair and secure search experience, contrasting with traditional platforms that often prioritize self-serving content. 
While Presearch's model promotes user empowerment through rewards and privacy, it faces the challenge of scaling its decentralized operations while maintaining competitive search result quality against industry giants.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363340/crypto-leaders-step-up-pressure-on-sec-as-trumps-policies-reshape-regulatory-landscape">Crypto Leaders Step Up Pressure On SEC As Trump&#8217;s Policies Reshape Regulatory Landscape</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Presearch Bolsters Web3 Transition With PRE Token Beta Launch On Base Layer 2

JP Morgan analyst Jamie Baker maintains Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Underweight and raises the price target from $25 to $30.

JP Morgan Maintains Underweight on Southwest Airlines, Raises Price Target to $30

Guidance

Corning Announces Upgrade To Its Springboard Plan; Raises 2023-2027 Sales CAGR Outlook In Optical Communications' Enterprise Business From 25% To 30%, Says Expects Q1 Sales To Exceed $3.6B And EPS At High End Of $0.48-$0.52 Range

<ul>
<li>Next-generation flexible pipes to offer 30-year service life in high CO2 environment</li>
</ul>
HOUSTON and LONDON –&nbsp;March 18, 2025&nbsp;– Baker Hughes, an energy technology company, announced Tuesday a joint technology development&nbsp;program with Petrobras to provide a definitive solution for stress corrosion cracking due to CO2 (SCC-CO2) in flexible pipe systems.&nbsp;
The pre-commercial agreement encompasses development and testing, as well as a purchase option of the resulting next-generation flexible pipes, which will have an extended service life of 30 years in high-CO2 environments. The collaborative effort between Baker Hughes and Petrobras will be primarily executed at Baker Hughes' Rio de Janeiro Energy Technology Innovation Center and nearby flexible pipe systems manufacturing plant.

Contracts

Baker Hughes Awarded First Technology Agreement With Petrobras To Develop Definitive Solution For Pipeline Corrosion

Offerings

REE Automotive Prices $27M Registered Direct Offering Of 6,376,631 Shares At $4.25/Share

ESLT

Elbit Systems shares are trading higher after the company reported better-than-expected Q4 financial results.

Strategy&#x2122; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>, STRK))) today announced that, subject to market and other conditions, it intends to offer, in a public offering registered under the Securities Act of 1933, as amended (the "Securities Act"), 5,000,000 shares of Strategy's Series A Perpetual Strife Preferred Stock (the "perpetual strife preferred stock").
Strategy intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of bitcoin and for working capital.
The perpetual strife preferred stock will accumulate cumulative dividends at a fixed rate of 10.00% per annum on the stated amount. Regular dividends on the perpetual strife preferred stock will be payable when, as and if declared by Strategy's board of directors, out of funds legally available for their payment, quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, beginning on June 30, 2025. Declared regular dividends on the perpetual strife preferred stock will be payable solely in cash. In the event that any accumulated regular dividend on the perpetual strife preferred stock is not paid on the applicable regular dividend payment date, then additional regular dividends ("compounded dividends") will accumulate on the amount of such unpaid regular dividend, compounded quarterly. The compounded dividend rate applicable to any unpaid regular dividend that was due on a regular dividend payment date will initially be a rate per annum equal to 10% plus 100 basis points; provided, however, that, until such regular dividend, together with compounded dividends thereon, is paid in full, such compounded dividend rate will increase by 100 basis points per annum for each subsequent regular dividend period, up to a maximum dividend rate of 18% per annum.
Strategy will have the right, at its election, to redeem all, but not less than all, of the perpetual strife preferred stock, at any time, for cash if the total number of shares of perpetual strife preferred stock then outstanding is less than 25% of the total number of shares of the perpetual strife preferred stock originally issued in the offering and any future offerings, taken together. In addition, Strategy will have the right to redeem all, but not less than all, of the perpetual strife preferred stock if certain tax events occur. The redemption price for any perpetual strife preferred stock to be redeemed will be a cash amount equal to the liquidation preference of the perpetual strife preferred stock to be redeemed as of the business day before the date on which Strategy sends the related redemption notice, plus accumulated and unpaid regular dividends to, but excluding, the redemption date.
If an event that constitutes a "fundamental change" under the certificate of designations governing the perpetual strife preferred stock occurs, then holders of the perpetual strife preferred stock will have the right to require Strategy to repurchase some or all of their shares of perpetual strife preferred stock at a cash repurchase price equal to the stated amount of the perpetual strife preferred stock to be repurchased, plus accumulated and unpaid regular dividends, if any, to, but excluding the fundamental change repurchase date.
The liquidation preference of the perpetual strife preferred stock shall initially be $100 per share (the "stated amount"). Effective immediately after the close of business on each business day after the initial issue date (and, if applicable, during the course of a business day on which any sale transaction to be settled by the issuance of perpetual strife preferred stock is executed, from the exact time of first such sale transaction during such business day until the close of business of such business day), the liquidation preference per share will be adjusted to be the greatest of (i) the stated amount; (ii) in the case of any business day with respect to which we have, on such business day or any business day during the ten trading day period preceding such business day, executed any sale transaction to be settled by the issuance of perpetual strife preferred stock, an amount equal to the last reported sale price per share of perpetual strife preferred stock on the trading day immediately before such business day; and (iii) the arithmetic average of the last reported sale prices per share of perpetual strife preferred stock for each trading day of the ten consecutive trading days (or, if applicable, the lesser number of trading days as have elapsed during the period from, and including, the initial issue date to, but excluding, such business day) immediately preceding such business day.
Morgan Stanley &amp; Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc. and Moelis &amp; Company LLCare acting as joint book-running managers for the offering.

Strategy Announces Public Offering Of 5M Shares Of Series A Perpetual Strife Preferred Stock; 10% Per Annum Dividend Rate; Net Proceeds For Bitcoin Acquisition, Working Capital; Redemption Rights, Liquidation Preference, And Compounded Dividends Detailed

"According To Recent Market Sources, Apple Intelligence's Key Component, The Powerful Ai Siri Virtual Assistant, Is In A Critical Development Stage And Will Almost Certainly Miss Its Scheduled Spring Introduction. This Information Was Not Publicly Disclosed But Spread Through Hearsay, Which Sparked Widespread Uproar." - DigiTimes Alert

B of A Securities analyst Kenneth Bruce maintains American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) with a Neutral and lowers the price target from $326 to $325.

B of A Securities Maintains Neutral on American Express, Lowers Price Target to $325

<ul>
<li>The company is expected to reduce core operational burn by 55% when compared to 2024</li>
</ul>

TCBP

TC BioPharm Announces Outsourcing Initiatives To Reduce Burn Rate And Overhead

Sjögren's disease (SjD)&nbsp;is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments&nbsp;&nbsp;
The Company is actively enrolling patients in the Phase 3 DAFFODIL study&nbsp;&nbsp;
This marks the fourth nipocalimab FDA Fast Track designation
SPRING HOUSE, Pa., March 18, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD) for the treatment of adult patients with moderate-to-severe Sjögren's disease (SjD), having previously been granted <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4384625-1&amp;h=3568246313&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fnipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjogrens-disease&amp;a=Breakthrough">Breakthrough</a>&nbsp;Therapy designation (BTD) for the investigational therapy late last year. Currently, no advanced therapies are approved to treat this disease.
Building upon the BTD, which nipocalimab is the first and only therapeutic to receive for&nbsp;SjD, the U.S. FDA's FTD is also designed to accelerate the delivery of new therapeutics to patients by facilitating the development and expediting the review of drugs that demonstrate the potential to treat serious conditions and help address unmet needs for serious or life-threatening conditions.

Biotech

General

Johnson & Johnson Announces That The U.S. FDA Has Granted Investigational Nipocalimab Fast Track Designation For The Treatment Of Adult Patients With Moderate-To-Severe Sjögren's Disease, Having Previously Been Granted Breakthrough Therapy Designation For The Investigational Therapy Late Last Year; No Advanced Therapies Are Approved To Treat This Disease

ATNM

Actinium Pharmaceuticals Announces A Clinical Trial Program For Solid Tumors Combining Actimab-A With PD-1 Checkpoint Inhibitors KEYTRUDA And OPDIVO; Clinical Proof Of Concept Data Expected In 2025

Comments

Genmab

뉴스

에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌